Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:allocates |
Randomized
|
| gptkbp:clinicalTrialPhase |
Phase 2
|
| gptkbp:clinicalTrialsGovURL |
https://clinicaltrials.gov/ct2/show/NCT03400917
|
| gptkbp:condition |
Kidney Cancer
Renal Cell Carcinoma |
| gptkbp:enrollment |
861
|
| https://www.w3.org/2000/01/rdf-schema#label |
NCT03400917
|
| gptkbp:intervention |
gptkb:Pembrolizumab
gptkb:Axitinib |
| gptkbp:location |
International (multiple countries)
|
| gptkbp:mask |
None (Open Label)
|
| gptkbp:primaryCompletionDate |
September 2018
|
| gptkbp:result |
Overall Survival
Progression-Free Survival |
| gptkbp:sponsor |
gptkb:Merck_Sharp_&_Dohme_LLC
|
| gptkbp:studyCompletionDate |
December 2022
|
| gptkbp:studyStartDate |
October 30, 2017
|
| gptkbp:studyTitle |
gptkb:A_Study_of_Pembrolizumab_(MK-3475)_in_Combination_With_Axitinib_as_First-Line_Treatment_for_Locally_Advanced_or_Metastatic_Renal_Cell_Carcinoma_(MK-3475-426/KEYNOTE-426)
|
| gptkbp:studyType |
Interventional
|
| gptkbp:bfsParent |
gptkb:glioblastoma
|
| gptkbp:bfsLayer |
5
|